Waldenstrom's macroglobulinemia

Research output: Contribution to journalArticle

89 Citations (Scopus)

Abstract

Waldenstrom's macroglobulinemia is a low-grade lymphoplasmacytic lymphoma. It has an overall incidence of 2.5/million/year. The median age at diagnosis is 63 years. The clinical manifestations are hepatomegaly (20%), splenomegaly (15%), and lymphadenopathy (15%). The most common symptom is fatigue related to a normochromic, normocytic anemia, and the median hemoglobin value at diagnosis is 10 gm/dl. All patients with Waldenstrom's macroglobulinemia have a circulating tumor marker, the monoclonal IgM protein. Occasionally high levels of the IgM monoclonal protein can produce a hyperviscosity syndrome manifested by oronasal bleeding. Occasionally retinal hemorrhage or serious neurologic complications, such as somnolence or coma, may occur. The most important prognostic factors are hemoglobin, age, weight loss, and a cryoglobulin. Therapy has included alkylating agents, particularly chlorambucil, purine nucleoside analogs such as fludarabine or cladribine, and most recently the use of rituximab. The median survival of symptomatic patients is 65 months. Patients without symptoms should not be treated.

Original languageEnglish (US)
Pages (from-to)63-67
Number of pages5
JournalOncologist
Volume5
Issue number1
StatePublished - 2000

Fingerprint

Waldenstrom Macroglobulinemia
Immunoglobulin M
Hemoglobins
Cladribine
Cryoglobulins
Purine Nucleosides
Retinal Hemorrhage
Chlorambucil
Hepatomegaly
Alkylating Agents
Splenomegaly
Tumor Biomarkers
Coma
Non-Hodgkin's Lymphoma
Nervous System
Fatigue
Anemia
Weight Loss
Proteins
Hemorrhage

Keywords

  • Chlorambucil
  • Fludarabine
  • Hyperviscosity
  • Lymphoma
  • Monoclonal gammopathy
  • Waldenstrom's macroglobulinemia

ASJC Scopus subject areas

  • Cancer Research
  • Hematology

Cite this

Waldenstrom's macroglobulinemia. / Gertz, Morie; Fonseca, Rafael; Rajkumar, S Vincent.

In: Oncologist, Vol. 5, No. 1, 2000, p. 63-67.

Research output: Contribution to journalArticle

@article{32d6f6cfb69247f7b03f7be3be03b097,
title = "Waldenstrom's macroglobulinemia",
abstract = "Waldenstrom's macroglobulinemia is a low-grade lymphoplasmacytic lymphoma. It has an overall incidence of 2.5/million/year. The median age at diagnosis is 63 years. The clinical manifestations are hepatomegaly (20{\%}), splenomegaly (15{\%}), and lymphadenopathy (15{\%}). The most common symptom is fatigue related to a normochromic, normocytic anemia, and the median hemoglobin value at diagnosis is 10 gm/dl. All patients with Waldenstrom's macroglobulinemia have a circulating tumor marker, the monoclonal IgM protein. Occasionally high levels of the IgM monoclonal protein can produce a hyperviscosity syndrome manifested by oronasal bleeding. Occasionally retinal hemorrhage or serious neurologic complications, such as somnolence or coma, may occur. The most important prognostic factors are hemoglobin, age, weight loss, and a cryoglobulin. Therapy has included alkylating agents, particularly chlorambucil, purine nucleoside analogs such as fludarabine or cladribine, and most recently the use of rituximab. The median survival of symptomatic patients is 65 months. Patients without symptoms should not be treated.",
keywords = "Chlorambucil, Fludarabine, Hyperviscosity, Lymphoma, Monoclonal gammopathy, Waldenstrom's macroglobulinemia",
author = "Morie Gertz and Rafael Fonseca and Rajkumar, {S Vincent}",
year = "2000",
language = "English (US)",
volume = "5",
pages = "63--67",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "1",

}

TY - JOUR

T1 - Waldenstrom's macroglobulinemia

AU - Gertz, Morie

AU - Fonseca, Rafael

AU - Rajkumar, S Vincent

PY - 2000

Y1 - 2000

N2 - Waldenstrom's macroglobulinemia is a low-grade lymphoplasmacytic lymphoma. It has an overall incidence of 2.5/million/year. The median age at diagnosis is 63 years. The clinical manifestations are hepatomegaly (20%), splenomegaly (15%), and lymphadenopathy (15%). The most common symptom is fatigue related to a normochromic, normocytic anemia, and the median hemoglobin value at diagnosis is 10 gm/dl. All patients with Waldenstrom's macroglobulinemia have a circulating tumor marker, the monoclonal IgM protein. Occasionally high levels of the IgM monoclonal protein can produce a hyperviscosity syndrome manifested by oronasal bleeding. Occasionally retinal hemorrhage or serious neurologic complications, such as somnolence or coma, may occur. The most important prognostic factors are hemoglobin, age, weight loss, and a cryoglobulin. Therapy has included alkylating agents, particularly chlorambucil, purine nucleoside analogs such as fludarabine or cladribine, and most recently the use of rituximab. The median survival of symptomatic patients is 65 months. Patients without symptoms should not be treated.

AB - Waldenstrom's macroglobulinemia is a low-grade lymphoplasmacytic lymphoma. It has an overall incidence of 2.5/million/year. The median age at diagnosis is 63 years. The clinical manifestations are hepatomegaly (20%), splenomegaly (15%), and lymphadenopathy (15%). The most common symptom is fatigue related to a normochromic, normocytic anemia, and the median hemoglobin value at diagnosis is 10 gm/dl. All patients with Waldenstrom's macroglobulinemia have a circulating tumor marker, the monoclonal IgM protein. Occasionally high levels of the IgM monoclonal protein can produce a hyperviscosity syndrome manifested by oronasal bleeding. Occasionally retinal hemorrhage or serious neurologic complications, such as somnolence or coma, may occur. The most important prognostic factors are hemoglobin, age, weight loss, and a cryoglobulin. Therapy has included alkylating agents, particularly chlorambucil, purine nucleoside analogs such as fludarabine or cladribine, and most recently the use of rituximab. The median survival of symptomatic patients is 65 months. Patients without symptoms should not be treated.

KW - Chlorambucil

KW - Fludarabine

KW - Hyperviscosity

KW - Lymphoma

KW - Monoclonal gammopathy

KW - Waldenstrom's macroglobulinemia

UR - http://www.scopus.com/inward/record.url?scp=0033621919&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033621919&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 63

EP - 67

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 1

ER -